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Abstract The Present work was designed to develop and validate an 
accurate, precise and rapid method for the estimation of Telmisartan as Active 
Pharmaceutical Ingredient (API) as well as in tablet dosage form and prepared 
spherical agglomerates by RP-HPLC. The developed method was found to 
be simple, accurate, precise and sensitive. The separation was achieved on an 
Isocratic High Pressure Liquid Chromatography (HPLC) (Thermo Scientific) 
using pumps Jasco PU 2080 Plus, UV detector, column oven (Jasco), and a 
Reverse Phase C-18 (phenyl) Column (25 cm x 4.6 mm) i.d., particle size 5 
µm. The HPLC system was run with flow rate: 0.8 ml/min Injection Volume: 
10µl and run time: 10 min, Detector temp: 40 oC. The method was validated 
for specificity, precision, linearity, and accuracy, robustness, LOD and LOQ 
parameters. The recovery range was within the range of 99.0–102.0% and 
the method could be successfully applied for the routine analysis of the drug 
substance as well as the spherical agglomerates prepared by crystallo co- 
agglomeration technique. 
Keywords: RP HPLC, Method Development, Telmisartan, tablet, Spherical 
agglomerates, Validation  
1. INTRODUCTION
Telmisartan is an angiotensin-II AT
1
 receptor antagonist with a binding affinity 










hours) and the largest volume of distribution. It is used to treat hypertension 
and prevent associated complications including stroke, heart attack, and renal 
failure. (15) This drug works by blocking the hormone angiotensin thereby 
relaxing blood vessels, causing them to (35). This drug may also be used to 
treat congestive heart failure and to help protect the kidneys from damage due 
to diabetes Prentice (1993). Telmisartan is used alone or in combination with 
other medications to treat high blood pressure. In addition to blocking the 
RAAS, telmisartan acts as a selective modulator of peroxisome proliferator-
activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose 
metabolism. It is believed that Telmisartan’s dual mode of action may provide 
protective benefits against the vascular and renal damage caused by diabetes 
and cardiovascular disease (CVD) (3). 
A good number of analytical methods have been developed for the 
determination of telmisartan in pure form and in pharmaceutical dosage forms. 
An UV Spectrophotometric method for the determination of telmisartan in 
tablet formulation has been already reported by (23) in which the absorbance 
maximum was found at wavelength 230nm. The developed and validated UV 
spectrophotometric method by using methanol as a solvent for estimation 
of telmisartan in API and in pharmaceutical dosage form has been reported 
by (9). A spectrophotometric dual wavelength method for simultaneous 
determination of hydrochloride and telmisartan in combined dosage form has 
been reported by (7). A UV spectrophotometric method  for the estimation of 
telmisartan in bulk and tablet dosage form  in which 0.1N NaOH was used 
as a diluent and the analysis was carried out at 234nm has been reported by 
(19). Several chromatographic methods were developed and reported for the 
estimation of telmisartan. A  UV spectrophotometry method for estimation 
of telmisartan in bulk and pharmaceutical dosage forms in which methanol 
was used as a solvent and the absorbance was measured at 296 nm has been 
reported by (19). A  spectrophotometric method for the determination of 
telmisartan in tablet dosage forms (18). A multi wavelength analysis for the 
simultaneous determination of amlodipine besylate and Telmisartan in bulk 
drug and dosage form by using UV spectrophotometer has been reported by 
(12). A UV spectrophotometric method for the simultaneous determination 
of telmisartan and hydrochlorothiazide in a pharmaceutical dosage form has 
been reported by (8). A simultaneous spectrophotometric method for the 
estimation of amlodipine besylate and telmisartan in a tablet dosage form has 
been reported by (29). A method for simultaneous estimation of telmisartan 
and hydrochlorothiazide using high performance thin layer chromatography 
(HPTLC) has been reported by (25). A method for the determination of 
telmisartan by HPTLC method has been reported by (5). A HPTLC method 
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for the simultaneous determination of telmisartan and amlodipinebesylate 
has been proposed by (6). A  HPTLC method for the simultaneous estimation 
of telmisartan and ramipril in combined dosage form by (14). A RP-HPLC 
method was reported by for the determination of telmisartan in solid dosage 
forms in the concentration range 2-14µg/mL. The observed retention time of 
telmisartan was about 7 minutes and the theoretical plate count at lower side 
was about 3345 has been reported by (30). 
A stability indicating method for the estimation of telmisartan related 
substances in tablet formulations which was well established to separate 
and determine about 7 related substances of telmisartan with the run time 
of 50 minutes has been reported by (6). A  HPLC method for the assay of 
telmisartan in human plasma has been developed by26). Fluorescent detector 
was used for the detection of telmisartan and naproxen was used as internal 
standard in this method. A reverse phase liquid chromatographic method for 
quantitative estimation of telmisartan in human plasma has been reported by 
(30). A reverse phased high performance liquid chromatographic method for 
the estimation of telmisartan in serum samples has been reported by Vijay 
(10). which involves run time of 10 minutes. The robustness of the method 
was not demonstrated. An isocratic RP-HPLC method was reported for the 
assay of telmisartan in pharmaceutical formulation by (10). The run time of 
the method was 10 minutes. A HPLC method for simultaneous estimation of 
telmisartan and ramipril in pharmaceutical formulations has been developed 
by (28). The run time observed as 15 minutes with 1.5mL/minute flow rate 
and the detection was done at 210 nm. RP-HPLC method for the determination 
of telmisartan in pure and pharmaceutical formulations has been reported 
by (27). HPLC method for simultaneous determination of telmisartan and 
hydrochlorothiazide in tablets with 15 minutes run time has been reported by 
(11). A spectrophotometric method for simultaneous estimation of amlodipine 
besylate and telmisartan in tablet dosage form was reported by (20). An UPLC 
method for estimation of related substances in telmisartan tablet dosage form 
was reported by (31). RP-HPLC method for estimation of telmisartan in a tablet 
dosage form has been reported by (13). A RP-HPLC method for simultaneous 
estimation of cilnidipine and telmisartan in combined tablet dosage form has 
been reported by (17). A rapid stability indicating simultaneous determination 
of hydrochlorothiazide, ramipril and telmisartan in combined dosage form 
by ultra performance liquid chromatography has been reported by (31). 
Development of UVspectrophotometric method for estimation and validation 
of telmisartan as a pure API has been reported by (4). UV spectrophotometric 
method for estimation and validation of telmisartan in bulk and tablet dosage 








HPLC with variable wavelength programmable UV-Visible detector and 
Rheodyne injector was employed for investigation The separation was achieved 
on a Isocratic HPLC (Thermo Scientific) using pumps Jasco PU 2080 Plus, 
UV detector, column oven (Jasco), and a Reverse Phase C-18 (phenyl) Column 
(25 cm x 4.6 mm) i.d., particle size 5 µm). A Sartorius analytical balance was 
used for weighing the materials.
2.2 Chemicals and Solvents
The reference sample of Telmisartan (API) was obtained from Meridian Medicare, 
Solan. The Formulation Telma (Telmisartan) was procured from the local 
market. The novel formulation containing Telmisartan spherical agglomerates 
was prepared by crystallo co- agglomeration. Preparation technique was selected 
from total of sixteen formulations prepared by altering the formulae and the 
spherical agglomerates showing improved micromeritic properties and best 
dissolution profile was selected for the present study.  Methanol and Acetonitrile 
(Both HPLC grade) were purchased from Merck India Ltd. The orthophosphoric 
acid (AR grade) was purchased from local market.
2.3 The mobile phase
A mixture of Acetonitrile: Phosphate buffer in the ratio of 90:10 v/v was 
prepared and used as mobile phase. The pH of this mobile phase was adjusted 
to 2.4 using orthophosphoric acid 
2.4 The Buffer Solution
About 2.72 g of potassium dihydrogen phosphate was diluted to 1000 mL with 
water containing 2ml triethylamine and sonicated. The pH was adjusted with 
orthophosphoric acid and then filtered through 0.45µ nylon filter.
2.5 Standard solution of the drug
For analysis 100 ppm standard solution was prepared, required concentrations 
were obtained from 100 ppm solution by appropriate dilution.
2.6 Sample (tablet) solution
The formulation tablets of Telmisartan (Telma - 20 mg) were crushed to give 
finely powdered material. From the Powder prepared a 10 µg/ml solution in 
mobile phase and then filtered through membrane filter paper.
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For developing the method, a systematic study of the effect of various factors 
was undertaken by varying one parameter at a time and keeping all other 
conditions constant. Method development consists of selecting the appropriate 
wavelength and choice of stationary and mobile phases. The following studies 
were conducted for this purpose.
3.1 Method Optimization
The method optimization was designed using different compositions of 
Mobile Phases. Variations in the flow rate of the mobile phase were adjusted in 
such a way so as to achieve a chromatogram with theoretical plates more than 
2000 and with tailing factor less than 2. The different trials were conducted 
to reach at an optimal chromatographical method which can be successfully 
validated.
3.1.1 Trial No. 1
The analysis was carried out by HPLC with the following chromatographic 
conditions. Consensus on chromatographic conditions was arrived on the basis 
of  telmisartan solubility and polarity.
Mobile phase: Mixture of phosphate buffer (pH 4.0) and acetonitrile (20: 80 v/v).
Detection : UV Detector 
Column : 250mm length, 4.6mm internal diameter, 5µm particle size, Aligent C18
Flow rate : 0.5 mL minute-1
Injection volume : 20 µL
Run time : 20 minutes
Column temperature : Ambient
The absorbance was found satisfactory at 296nm at which the peak response 
was found on higher side due to injection overload. The back pressure of the 
column was found significantly low and the retention time was observed as 13 
minutes.
3.1.2 Trial No. 2
Based on the observed ƛmax, the optimum wavelength for the detection was set 
as 296 nm. The injection volume was reduced to 20µL to optimize the injection 
load and flow rate was increased to 0.8mL minute-1 to increase the desired 
back pressure to the column and to reduce the retention time of telmisartan. 






Figure 1: Chromatiogram of Trial 2
Mobile phase: Mixture of pH 4.4 phosphate buffer and acetonitrile (20: 80 v/v).
Detection : 296nm
Column : 250mm length, 4.6mm internal diameter, 5µm particle size, Aligent C18
Flow rate : 0.8 mL minute-1
Injection volume : 10µL
Run time : 15 minutes
Column temperature : Ambient
The peak symmetry of telmisartan and response were found satisfactory. The 
retention time of telmisartan was found about 7 minutes which need to be 
reduced.
3.1.3 Trial No. 3
To reduce the retention time of telmisartan, the mobile phase was optimized by 
increasing the acetonitrile composition in the mobile phase. 
The chromatogram for the standard was recorded under the above mentioned 
conditions. The peak symmetry was found good with the retention time of 
telmisartan at about 5.37 minutes.
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The spectrum of 10µg/ml solution of the Telmisartan in methanol was recorded 
separately on UV spectrophotometer. The peak of maximum absorbance 
wavelength was observed. The spectra of Telmisartan were showed maximum 
absorbance at 296nm.
3.3 Choice of stationary phase
Preliminary development trials have performed with octadecyl columns with 
different types, configurations and from different manufacturers. Finally the 
expected separation and peak shapes were obtained on Reverse Phase C-18 
(phenyl) Column (25 cm x 4.6 mm) i.d., particle size 5 µm.
3.4 Selection of the mobile phase
In order to get sharp peak, low tailing factor and base line separation of the 
separation of the components, a number of experiments were carried out by 
varying the composition of various solvents and flow rate. To have an ideal 
separation of the drug under isocratic conditions, mixtures of solvents like 
methanol, water and Acetonitrile with or without different buffers indifferent 
combinations were tested as mobile phases using C18 column. A mixture of 
Acetonitrile: phosphate buffer  in the ratio of 90:10 v/v was proved to be the 
most suitable of all the combinations since the chromatographic peak obtained 
was better defined and resolved and almost free from tailing.
3.5 Flow rate
Flow rates of the mobile phase were changed from 0.5 – 1.0 mL/min for 
optimum separation. A minimum flow rate as well as minimum run time gives 
the maximum saving on the usage of solvents. It was found from the experiments 
that 0.8 mL/min flow rate was ideal for the successful elution of the analyte.
Mobile phase: Mixture of pH 4.0 phosphate buffer and acetonitrile (10 : 90 v/v).
Detection : 296nm
Column : 250mm length, 4.6mm internal diameter, 5µm particle size, Aligent C18
Flow rate : 0.8 mL minute-1
Injection volume : 10µL
Run time : 08 minutes






4. VALIDATION OF THE PROPOSED METHOD
The proposed method was validated as per ICH guidelines. The parameters 
studied for validation were specificity, linearity, precision, accuracy, 
robustness, system suitability, limit of detection, limit of quantification, and 
solution stability (24).  
4.1 Specificity
The specificity of method was performed by comparing the chromatograms 
of blank, standard and sample (Prepared from Formulation)and the spherical 
agglomerates. It was found that there is no interference due to excipients in the 
tablet formulation and also found good correlation between the retention times 
of standard and sample. The specificity results are shown in Table 2. 
Table 2: Specificity study.




Table 1: Optimized chromatographic conditions for estimation of Telmisartan.
Mobile phase ACN: phosphate buffer  90:10 w/v
Pump mode Isocratic
Mobile phase PH 2.4
Diluent Mobile phase
   Column C-18 (phenyl) Column (25 cm x 4.6 mm) i.d. 5 µm.
Column Temp Ambient
Wavelength 296 nm
Injection Volume 10 µl
Flow rate 0.8 mL/min
Run time 10 min
Retention Time 5.36 min
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Linearity was performed by preparing mixed standard solutions 
of Telmisartan at different concentration levels including working 
concentration mentioned in experimental condition i.e. 10µg/ml. Twenty 
micro liters of each concentration was injected in duplicate into the 
HPLC system. The response was read at 296 nm and the corresponding 
chromatograms were recorded. From these chromatograms, the mean peak 
areas were calculated and linearity plots of concentration over the mean 
peak areas were constructed individually. The regressions of the plots 
were computed by least square regression method. Linearity results were 
presented in Table 3.
Table 3: Linearity results.














Precision is the degree of repeatability of an analytical method under normal 
operational conditions. The method was performed to evaluate intraday 
precision as well as inter day precision.
4.3.1 Intraday precision
To study the intraday precision, six replicate standard solutions (10µg/ml) of 
Telmisartan were injected. The percent relative standard deviation (% RSD) 
was calculated and it was found to be 0.0731, which are well within the 
acceptable criteria of not more than 2.0. Results of system precision studies 






Table 4: System Precision (Intra Day).




















4.3.2 Inter Day precision
To study the interday precision, six replicate standard solution of Telmisartan 
was injected on third day of sample preparation. The percent relative standard 
deviation (% RSD) was calculated and it was found to be 0.105, which are well 
within the acceptable criteria of not more than 2.0. Results of system precision 
studies are shown in Table 5.
4.4 Accuracy
The accuracy of the method was determined by standard addition method. 
A known amount of standard drug was added to the fixed amount of pre-
analyzed tablet solution. Percent recovery was calculated by comparing the 
area before and after the addition of the standard drug. The standard addition 
method was performed at 80%, 100% and 120% level of 10ppm. The 
solutions were analyzed in triplicate at each level as per the proposed method. 
The percent recovery and % RSD was calculated and results are presented 
in Table 6. Satisfactory recoveries ranging from 99.0 to 101.0 were obtained 
by the proposed method. This indicated that the proposed method was 
accurate.
4.5 Robustness
The robustness study was performed by slight modification in flow rate 
of Mobile phase, pH of the buffer and composition of the mobile phase. 
Telmisartan at 6 ppm concentration was analyzed under these changed 
experimental conditions. It was observed that there were no marked changes 
in chromatograms, which demonstrated that the developed method was robust 
in nature. The results of robustness study are shown in Table 7.
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Table 6: Percentage Recovery and % RSD.
Level
Amount of Amount of
% Recovery %RSDTelmisartan Telmisartan
80 % 6 5.97 99.5 0.118
6 5.96 99.33
6 5.95 99.16
100% 8 7.96 99.5 0.177
8 7.98 99.75
8 7.97 99.62
120% 10 9.97 99.7 0.498
10 9.90 99.0
10 9.94 99.4
Mean % of Mean
recovery 99.44 RSD =0.461
4.6 System suitability
System suitability was studied under each validation parameters by injecting 
six replicates of the standard solution 5 ppm). The results obtained were within 
acceptable limits (Tailing factor ≤2 and Theoretical plate’s ≥2000) and are 







Condition Mean area % assay % difference
Unaltered 407910 100.0 0.0
Flow rate at 0.6 mL/min 403985 99.03 0.97
Flow rate at 1.0 mL/min 404398 99.13 0.87
Mobile phase:
ACN : Buffer 
70% 30% 403587 98.9 0.10
80% 20 % 404405 99.15 0.85
pH of mobile phase at 2.0 404698 99.25 0.75
pH of mobile phase at 3.0 408724 100.19 0.19




Specificity study 1.71 5680
Linearity study 1.20 6694
Precision study 1.71 6705
4.7 Limit of Detection and Limit of Quantification
Limit of detection (LOD) is defined as the lowest concentration of analyte 
that gives a detectable response. Limit of quantification (LOQ) is defined 
as the lowest Concentration that can be quantified reliably with a specified 
level of accuracy and Precision. For this sample was dissolved by using 
Mobile Phase and injected until peak was disappeared. After 0.86 ng/ml 
dilution, Peak was not clearly observed. So it confirms that 15 ng is limit 
of Detection and 2.62 ng dilutions is Limit of Quantification. For this study 
six replicates of the analyte at lowest concentration were Measured and 
quantified. The LOD and LOQ of Telmisartan are given in Table 9.
Table 9 : LOD and LOQ.
Parameter Measured Value ng/mL
Limit of Detection 0.72
Limit of Quantification 2.02
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5. ASSAY OF MARKETED TABLET FORMULATION
The proposed method was applied to the assay of commercial tablets containing 
Telmisartan. Sample was analyzed for five times after extracting the drug as 
mentioned in assay sample preparation of the experimental section. After 
analysis test result assay of Telmisartan in Tablet was found to be 19.27% 
which was very close to the labeled amount.
6. ASSAY OF PREPARED SPHERICAL AGGLOMERATES
The proposed method was applied to the assay of tablets containing Telmisartan 
spherical agglomerates.. Sample was analyzed for five times after extracting 
the drug as mentioned in assay sample preparation of the experimental section. 
After analysis test result assay of Telmisartan in spherical agglomerates was 
18.52 and is very close to the labeled amount
DISCUSSION 
To optimize the RP-HPLC parameters, several mobile phase compositions 
were evaluated. A satisfactory separation and good peak symmetry was found 
in a mixture of Acetonitrile: Buffer in the ratio of 90:10 w/v and 0.8 mL/
min flow rate proved to be better combination than the other combinations in 
terms of resolution and peak shape. The optimum wavelength for detection 
was set at 296 nm at which much better detector responses for drug were 
obtained. As is evident from Figure 2 the retention times were 5.36 min for 
Telmisartan. The number of theoretical plates was found to be 5680, which 






indicates efficient performance of the column. A system suitability test was 
applied to representative chromatograms for various parameters. The results 
obtained were within acceptable limits and are represented in Table 8. Thus, 
the system meets suitable criteria. The calibration curve was obtained for a 
series of concentration in the range of 5-30µg/ml and it was found to be linear. 
Seven points graphs was constructed covering a concentration range 5-30µg/
ml. The standard deviation of the slope and intercept were low. The data of 
regression analysis of the calibration curves are shown in Table. Calibration 
curve found to be linear with r2=0.999, Intercept (-2438) and Slope (40802) 
respectively. The results obtained were within acceptable limits where 
capacity factor >2.0, tailing factor ≤2.0 and theoretical plates >2000.  In all 
cases, the relative standard deviation (R.S.D) for the analytic peak area for two 
consecutive injections was < 2.0%.
Precision was evaluated by carrying out six independent sample preparation 
of a single lot of formulation. Low values of standard deviation denoted very 
good repeatability of the measurement. Thus it was showing that the equipment 
used for the study was correct and hence the developed analytical method is 
highly repetitive. RSD of intraday precision was found to 0.0731. For the 
interday precision a study carried out on consecutive days indicated a RSD of 
0.105. This indicates good method precision. 
Standard addition method at 80%, 100% and 120% to the proposed HPLC 
method is carried out to find the Accuracy of the Telmisartan. The results 
showed good recoveries ranging from 99.00 to 101 %. 
The proposed method has been applied to the assay of commercial tablets 
containing Telmisartan. Sample was analyzed for five times after extracting the 
drug as mentioned in assay sample preparation of the experimental section. The 
results (19.27%) presented good agreement with the labeled content. Low values 
of standard deviation denoted very good repeatability of the measurement.
The proposed method has been applied to the assay of tablets containing 
Telmisartan spherical agglomerates.. Sample was analyzed for five times 
after extracting the drug as mentioned in assay sample preparation of the 
experimental section. After analysis test result assay of Telmisartan in Tablet 
formulation is 18.52% and is very close to the labeled amount.
The statistical evaluation of the proposed method was revealed its good 
linearity, reproducibility and its validation for different parameters and let us 
to the conclusion that it could be used for the rapid and reliable determination 
of Telmisartan in tablet Marketed formulation and tablets prepared using 
the spherical agglomerates. All these factors lead to the conclusion that the 
proposed method is accurate, precise, simple, sensitive and rapid and can 
be applied successfully for the estimation of Telmisartan in bulk and in 
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pharmaceutical formulations without interference and with good sensitivity. 
The proposed method has opened doors to develop a bioanalytical method to 




 can then 
be calculated to determine the bioavailability of Telmisartan agglomerates 
prepared by CCA method using polymers.   
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